Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Echols · SciRah

Researcher profile · Semantic Scholar

R. Echols

Share profile

R. Echols — researcher profile on SciRah

h-index: 37
Works: 155
Citations: 5,071

Most-cited papers

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
M. Bassetti, R. Echols, Y. Matsunaga, M. Ariyasu +11 more
2020Lancet. Infectious Diseases (Print)602 citations
Semantic Scholar
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
R. Wunderink, Y. Matsunaga, M. Ariyasu, P. Clevenbergh +9 more
2020Lancet. Infectious Diseases (Print)392 citations
Semantic Scholar
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
S. Portsmouth, D. V. Van Veenhuyzen, R. Echols, M. Machida +4 more
2018Lancet. Infectious Diseases (Print)336 citations
Semantic Scholar
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
M. Hackel, M. Tsuji, Y. Yamano, R. Echols +2 more
2017Antimicrobial Agents and Chemotherapy208 citations Open access
Semantic Scholar
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
M. Hackel, M. Tsuji, Y. Yamano, R. Echols +2 more
2017Antimicrobial Agents and Chemotherapy188 citations Open access
Semantic Scholar
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
K. Kazmierczak, M. Tsuji, M. Wise, M. Hackel +3 more
2019International Journal of Antimicrobial Agents173 citations Open access
Semantic Scholar
Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa
B. Cai, R. Echols, G. Magee, J. A. Arjona Ferreira +4 more
2017Open Forum Infectious Diseases166 citations Open access
Semantic Scholar
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
J. Karlowsky, M. Hackel, M. Tsuji, Y. Yamano +2 more
2019International Journal of Antimicrobial Agents134 citations Open access
Semantic Scholar
Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.
M. Hackel, M. Tsuji, Y. Yamano, R. Echols +2 more
2019Diagnostic microbiology and infectious disease118 citations Open access
Semantic Scholar
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies
J. Timsit, M. Paul, R. Shields, R. Echols +3 more
2022Clinical Infectious Diseases103 citations Open access
Semantic Scholar
Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
T. Katsube, R. Echols, J. A. Arjona Ferreira, H. Krenz +2 more
2016Journal of clinical pharmacology96 citations Open access
Semantic Scholar
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
T. Katsube, R. Echols, T. Wajima
2019Clinical Infectious Diseases94 citations Open access
Semantic Scholar
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model
M. Monogue, M. Tsuji, Y. Yamano, R. Echols +1 more
2017Antimicrobial Agents and Chemotherapy89 citations Open access
Semantic Scholar
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
S. Matsumoto, Christine M. Singley, J. Hoover, Rio Nakamura +4 more
2017Antimicrobial Agents and Chemotherapy87 citations Open access
Semantic Scholar
In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
J. Karlowsky, M. Hackel, M. Takemura, Y. Yamano +2 more
2021Antimicrobial Agents and Chemotherapy86 citations Open access
Semantic Scholar
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function
T. Katsube, T. Wajima, T. Ishibashi, J. A. Arjona Ferreira +1 more
2016Antimicrobial Agents and Chemotherapy82 citations Open access
Semantic Scholar
In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
C. Longshaw, D. Manissero, M. Tsuji, R. Echols +1 more
2020JAC-Antimicrobial Resistance73 citations Open access
Semantic Scholar
Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials
P. Nordmann, R. Shields, Y. Doi, M. Takemura +3 more
2022Microbial Drug Resistance67 citations Open access
Semantic Scholar
Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance
J. Rex, G. Talbot, M. Goldberger, B. Eisenstein +4 more
2017Clinical Infectious Diseases63 citations Open access
Semantic Scholar
Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
G. Talbot, Anita F. Das, Stephanie S. Cush, A. Dane +9 more
2019Journal of Infectious Diseases61 citations Open access
Semantic Scholar
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
N. Kawaguchi, T. Katsube, R. Echols, T. Wajima
2020Antimicrobial Agents and Chemotherapy57 citations Open access
Semantic Scholar
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies
T. Lodise, M. Bassetti, R. Ferrer, T. Naas +4 more
2021Expert Review of Anti-Infective Therapy54 citations Open access
Semantic Scholar
The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study
B. Cai, G. Tillotson, D. Benjumea, P. Callahan +1 more
2020Open Forum Infectious Diseases54 citations Open access
Semantic Scholar
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia
T. Katsube, D. Nicolau, K. Rodvold, R. Wunderink +5 more
2021Journal of Antimicrobial Chemotherapy53 citations Open access
Semantic Scholar
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
N. Kawaguchi, T. Katsube, R. Echols, T. Wajima
2017Antimicrobial Agents and Chemotherapy48 citations Open access
Semantic Scholar
In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019
M. Wise, J. Karlowsky, M. Hackel, M. Takemura +3 more
2023Microbial Drug Resistance36 citations Open access
Semantic Scholar
The prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence.
M. Kollef, H. Dupont, D. Greenberg, P. Viale +3 more
2023International Journal of Antimicrobial Agents30 citations Open access
Semantic Scholar
Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study
M. Bassetti, M. Ariyasu, B. Binkowitz, Tsutae Den Nagata +4 more
2019Infection and Drug Resistance29 citations Open access
Semantic Scholar
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
R. Echols, M. Ariyasu, Tsutae Den Nagata
2019Clinical Infectious Diseases28 citations Open access
Semantic Scholar
Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
S. Stainton, M. Monogue, M. Tsuji, Y. Yamano +2 more
2018Antimicrobial Agents and Chemotherapy28 citations Open access
Semantic Scholar
Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)
S. Portsmouth, D. V. Van Veenhuyzen, R. Echols, M. Machida +3 more
201727 citations Open access
Semantic Scholar
In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii
C. Gill, Debora Santini, M. Takemura, C. Longshaw +3 more
2023Journal of Antimicrobial Chemotherapy25 citations Open access
Semantic Scholar
Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects
N. Kawaguchi, T. Katsube, R. Echols, T. Wajima +1 more
2021Journal of clinical pharmacology25 citations Open access
Semantic Scholar
1065. Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits
V. Petraitis, R. Petraitienė, P. Kavaliauskas, E. Naing +7 more
2021Antimicrobial Agents and Chemotherapy19 citations Open access
Semantic Scholar
1266. Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies
M. Takemura, Y. Yamano, Y. Matsunaga, M. Ariyasu +2 more
2020Open Forum Infectious Diseases16 citations Open access
Semantic Scholar
Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections
Casey Doremus, S. Marcella, B. Cai, R. Echols
2021Infectious Disease and Therapy15 citations Open access
Semantic Scholar
Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies
D. Paterson, M. Kinoshita, Takamichi Baba, R. Echols +1 more
2022Infectious Disease and Therapy14 citations Open access
Semantic Scholar
1455. Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies
Y. Yamano, Rio Nakamura, M. Takemura, R. Echols
2020Open Forum Infectious Diseases14 citations Open access
Semantic Scholar
LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority Study
R. Wunderink, Y. Matsunaga, Mari Ari, M. Ariyasu +3 more
2019Open Forum Infectious Diseases14 citations Open access
Semantic Scholar
DTR, do we need a new definition?
R. Echols, G. Tillotson
2019Clinical Infectious Diseases11 citations
Semantic Scholar
Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials
S. Portsmouth, Almasa Bass, R. Echols, G. Tillotson
2021Open Forum Infectious Diseases9 citations Open access
Semantic Scholar
1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
Y. Yamano, M. Takemura, C. Longshaw, R. Echols
2020Open Forum Infectious Diseases9 citations Open access
Semantic Scholar
1626. Synergistic Effect of Cefiderocol with Other Antibiotics Against PER-Producing Acinetobacter baumannii Isolates from the Multinational SIDERO-WT Studies
Y. Yamano, M. Takemura, Naomi Anan, Rio Nakamura +1 more
2020Open Forum Infectious Diseases8 citations Open access
Semantic Scholar
1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
Y. Matsunaga, T. Sonoyama, Luis Casanova, Tsutae Den Nagata +4 more
2020Open Forum Infectious Diseases8 citations Open access
Semantic Scholar
Placing in-vitro heteroresistance in the context of clinical results.
M. Bassetti, R. Echols, A. Koren, A. Karas +3 more
2021Lancet. Infectious Diseases (Print)7 citations Open access
Semantic Scholar
1452. Molecular Profile of β-Lactamase Genes and Siderophore-Dependent Iron Transporter Genes of Cefiderocol High MIC Isolates from SIDERO-WT Studies
Y. Yamano, M. Takemura, K. Kazmierczak, M. Wise +3 more
2020Open Forum Infectious Diseases6 citations Open access
Semantic Scholar
In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
M. Tsuji, M. Hackel, R. Echols, Y. Yamano +1 more
2017Open Forum Infectious Diseases6 citations Open access
Semantic Scholar
Erratum for Karlowsky et al., “In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019”
J. Karlowsky, M. Hackel, M. Takemura, Y. Yamano +2 more
2023Antimicrobial Agents and Chemotherapy5 citations Open access
Semantic Scholar
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study
Eric P. Skaar, R. Echols, Y. Matsunaga, A. Menon +1 more
2022European Journal of Clinical Microbiology and Infectious Diseases5 citations Open access
Semantic Scholar
Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation
S. Portsmouth, R. Echols, Kiichiro Toyoizumi, G. Tillotson +1 more
2021Therapeutic Advances in Infectious Disease5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Y. Yamano×24
Invite
Y. Yamano — researcher profile on SciRah
S. Portsmouth×10
Invite
S. Portsmouth — researcher profile on SciRah
M. Tsuji×10
Invite
M. Tsuji — researcher profile on SciRah
D. Sahm×10
Invite
D. Sahm — researcher profile on SciRah

×10

Invite

M. Takemura — researcher profile on SciRah

Y. Matsunaga×9

Invite

Y. Matsunaga — researcher profile on SciRah

Invite

M. Ariyasu — researcher profile on SciRah

Tsutae Den Nagata×9

Invite

Tsutae Den Nagata — researcher profile on SciRah

Invite

M. Hackel — researcher profile on SciRah

J. Karlowsky×7

Invite

J. Karlowsky — researcher profile on SciRah

Invite

T. Katsube — researcher profile on SciRah

Invite

T. Wajima — researcher profile on SciRah